Literature DB >> 10474821

Noscapine hydrochloride disrupts the mitotic spindle in mammalian cells and induces aneuploidy as well as polyploidy in cultured human lymphocytes.

M Schuler1, P Muehlbauer, P Guzzie, D A Eastmond.   

Abstract

Noscapine hydrochloride is a centrally acting antitussive opium derivative widely used in cough suppressants. Recent studies have reported that noscapine is a potent inducer of polyploidy but not of aneuploidy in vitro. To obtain more comprehensive information about the cytogenetic effects of this compound, we treated cultured human lymphocytes (HPL) and Chinese hamster ovary (CHO) cells with various concentrations of noscapine hydrochloride. Using a differential staining technique noscapine was shown to disrupt the mitotic spindle at concentrations < 5 micrograms/ml in both cell types. The use of multicolor fluorescence in situ hybridization (FISH) on noscapine-treated human lymphocytes showed a dose-dependent induction of hyperdiploidy of chromosome 1 but not of chromosomal breakage in the 1cen-q12 region under in vitro conditions, indicating that noscapine is specifically inducing numerical chromosomal aberrations. FISH with probes targeting different chromosomes revealed that noscapine is capable of inducing both polyploidy and true hyperdiploidy. Our results show that noscapine, by disrupting the function of the mitotic spindle, has the ability to induce aneuploidy and not uniquely polyploidy as previously reported. By using these types of molecular cytogenetic techniques, it should be possible to evaluate the ability of noscapine to induce aneuploidy in the upper intestinal tract in vivo.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10474821     DOI: 10.1093/mutage/14.1.51

Source DB:  PubMed          Journal:  Mutagenesis        ISSN: 0267-8357            Impact factor:   3.000


  7 in total

1.  Aneugen Molecular Mechanism Assay: Proof-of-Concept With 27 Reference Chemicals.

Authors:  Derek T Bernacki; Steven M Bryce; Jeffrey C Bemis; Stephen D Dertinger
Journal:  Toxicol Sci       Date:  2019-08-01       Impact factor: 4.849

2.  Effect of met-enkephalin on chromosomal aberrations in the lymphocytes of the peripheral blood of patients with multiple sclerosis.

Authors:  Maida Rakanović-Todić; Lejla Burnazović-Ristić; Slavka Ibrulj; Nedžad Mulbegović
Journal:  Bosn J Basic Med Sci       Date:  2014-05       Impact factor: 3.363

3.  Interlaboratory evaluation of a multiplexed high information content in vitro genotoxicity assay.

Authors:  Steven M Bryce; Derek T Bernacki; Jeffrey C Bemis; Richard A Spellman; Maria E Engel; Maik Schuler; Elisabeth Lorge; Pekka T Heikkinen; Ulrike Hemmann; Véronique Thybaud; Sabrina Wilde; Nina Queisser; Andreas Sutter; Andreas Zeller; Melanie Guérard; David Kirkland; Stephen D Dertinger
Journal:  Environ Mol Mutagen       Date:  2017-04       Impact factor: 3.216

4.  Metabolic map and bioactivation of the anti-tumour drug noscapine.

Authors:  Zhong-Ze Fang; Kristopher W Krausz; Fei Li; Jie Cheng; Naoki Tanaka; Frank J Gonzalez
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

5.  In vitro human cell-based aneugen molecular mechanism assay.

Authors:  Nikki E Hall; Kyle Tichenor; Steven M Bryce; Jeffrey C Bemis; Stephen D Dertinger
Journal:  Environ Mol Mutagen       Date:  2022-04-22       Impact factor: 3.579

6.  Predictions of genotoxic potential, mode of action, molecular targets, and potency via a tiered multiflow® assay data analysis strategy.

Authors:  Stephen D Dertinger; Andrew R Kraynak; Ryan P Wheeldon; Derek T Bernacki; Steven M Bryce; Nikki Hall; Jeffrey C Bemis; Sheila M Galloway; Patricia A Escobar; George E Johnson
Journal:  Environ Mol Mutagen       Date:  2019-02-27       Impact factor: 3.216

7.  Genotoxic mode of action predictions from a multiplexed flow cytometric assay and a machine learning approach.

Authors:  Steven M Bryce; Derek T Bernacki; Jeffrey C Bemis; Stephen D Dertinger
Journal:  Environ Mol Mutagen       Date:  2016-01-13       Impact factor: 3.216

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.